Why the study?
What are the mechanisms and recommended prophylactic antithrombotic therapies for chemotherapy-associated thrombosis in cancer patients?
What are the mechanisms and recommended prophylactic antithrombotic therapies for chemotherapy-associated thrombosis in cancer patients?
This review summarizes the pathophysiology of chemotherapy-associated thrombosis and outlines current recommendations for prophylactic antithrombotic therapy in cancer patients.
No takes yet. Share an insight, caveat, or question.
Offers clinicians a synthesis of antineoplastic thrombosis risks and prophylaxis; leaves open the need for randomized data to refine recommendations.
Oppelt et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: